Literature DB >> 25270431

Targeting DNA vaccines to myeloid cells using a small peptide.

Chunting Ye1, Jang Gi Choi, Sojan Abraham, Premlata Shankar, N Manjunath.   

Abstract

Targeting DNA vaccines to dendritic cells (DCs) greatly enhances immunity. Although several approaches have been used to target protein Ags to DCs, currently there is no method that targets DNA vaccines directly to DCs. Here, we show that a small peptide derived from the rabies virus glycoprotein fused to protamine residues (RVG-P) can target DNA to myeloid cells, including DCs, which results in enhanced humoral and T-cell responses. DCs targeted with a DNA vaccine encoding the immunodominant vaccinia B8R gene via RVG-P were able to restimulate vaccinia-specific memory T cells in vitro. Importantly, a single i.v. injection of B8R gene bound to RVG-P was able to prime a vaccinia-specific T-cell response that was able to rapidly clear a subsequent vaccinia challenge in mice. Moreover, delivery of DNA in DCs was enough to induce DC maturation and efficient Ag presentation without the need for adjuvants. Finally, immunization of mice with a DNA-vaccine encoding West Nile virus (WNV) prM and E proteins via RVG-P elicited high titers of WNV-neutralizing Abs that protected mice from lethal WNV challenge. Thus, RVG-P provides a reagent to target DNA vaccines to myeloid cells and elicit robust T-cell and humoral immune responses.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Antigen targeting; DNA vaccine; Dendritic cells; Immune response; Rabies virus glycoprotein peptide

Mesh:

Substances:

Year:  2014        PMID: 25270431      PMCID: PMC4293249          DOI: 10.1002/eji.201445010

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  32 in total

1.  Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo.

Authors:  Daniel Hawiger; Revati F Masilamani; Estelle Bettelli; Vijay K Kuchroo; Michel C Nussenzweig
Journal:  Immunity       Date:  2004-06       Impact factor: 31.745

Review 2.  Recent advances towards the clinical application of DNA vaccines.

Authors:  A D Bins; J H van den Berg; K Oosterhuis; J B A G Haanen
Journal:  Neth J Med       Date:  2013-04       Impact factor: 1.422

3.  Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response.

Authors:  Matthias Tenbusch; Godwin Nchinda; Michael Storcksdieck genannt Bonsmann; Vladimir Temchura; Klaus Überla
Journal:  Int Immunol       Date:  2012-11-26       Impact factor: 4.823

4.  Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.

Authors:  Philip J Bergman; Joanne McKnight; Andrew Novosad; Sarah Charney; John Farrelly; Diane Craft; Michelle Wulderk; Yusuf Jeffers; Michel Sadelain; Ann E Hohenhaus; Neil Segal; Polly Gregor; Manuel Engelhorn; Isabelle Riviere; Alan N Houghton; Jedd D Wolchok
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

5.  Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis.

Authors:  Diego Delgado; Ana del Pozo-Rodríguez; Maria Ángeles Solinís; Marcelino Avilés-Triqueros; Bernhard H F Weber; Eduardo Fernández; Alicia R Gascón
Journal:  Hum Gene Ther       Date:  2012-03-29       Impact factor: 5.695

6.  Single chain antibody fragments for the selective targeting of antigens to dendritic cells.

Authors:  Caroline Demangel; Jie Zhou; Andre B H Choo; Grant Shoebridge; Gary M Halliday; Warwick J Britton
Journal:  Mol Immunol       Date:  2004-12-10       Impact factor: 4.407

7.  West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays.

Authors:  B S Davis; G J Chang; B Cropp; J T Roehrig; D A Martin; C J Mitchell; R Bowen; M L Bunning
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines.

Authors:  David C Tscharke; Gunasegaran Karupiah; Jie Zhou; Tara Palmore; Kari R Irvine; S M Mansour Haeryfar; Shanicka Williams; John Sidney; Alessandro Sette; Jack R Bennink; Jonathan W Yewdell
Journal:  J Exp Med       Date:  2004-12-28       Impact factor: 14.307

9.  Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.

Authors:  Laura Bonifaz; David Bonnyay; Karsten Mahnke; Miguel Rivera; Michel C Nussenzweig; Ralph M Steinman
Journal:  J Exp Med       Date:  2002-12-16       Impact factor: 14.307

10.  In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.

Authors:  Laura C Bonifaz; David P Bonnyay; Anna Charalambous; Dara I Darguste; Shin-Ichiro Fujii; Helena Soares; Marie K Brimnes; Bruno Moltedo; Thomas M Moran; Ralph M Steinman
Journal:  J Exp Med       Date:  2004-03-15       Impact factor: 14.307

View more
  4 in total

Review 1.  DNA vaccines for prostate cancer.

Authors:  Christopher D Zahm; Viswa Teja Colluru; Douglas G McNeel
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

Review 2.  Molecular mechanisms for enhanced DNA vaccine immunogenicity.

Authors:  Lei Li; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2015-12-28       Impact factor: 5.217

Review 3.  Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach.

Authors:  Titus Abiola Olukitibi; Zhujun Ao; Mona Mahmoudi; Gary A Kobinger; Xiaojian Yao
Journal:  Microorganisms       Date:  2019-09-29

4.  Targeted Delivery of Nanovaccine to Dendritic Cells via DC-Binding Peptides Induces Potent Antiviral Immunity in vivo.

Authors:  Ying Lu; Ze-Hui Liu; Ying-Xiang Li; Hui-Ling Xu; Wei-Huan Fang; Fang He
Journal:  Int J Nanomedicine       Date:  2022-04-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.